亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study

作者
Kathleen L. Deering,Murali Sundaram,Qing Harshaw,Jeremiah Trudeau,Jacqueline C. Barrientos
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:17 (10): e0270291-e0270291 被引量:8
标识
DOI:10.1371/journal.pone.0270291
摘要

The objective of this study was to describe real-world health-related quality of life (HRQoL) and treatment satisfaction of ibrutinib-treated patients with CLL compared to a reference group. This study was completed in two parts. The first portion (Norming Study) was a US online survey conducted to serve as a reference population. The Norming Study included a total of 139 patients with CLL, excluding those treated with ibrutinib: 64 were treatment naive (Tx naive), 36 were 1st line (1L), and 38 were in or had completed ≥2 lines (2L+) patients with CLL. The second portion (CLL Ibrutinib Study) included 1L and 2L+ ibrutinib patients with CLL treated for ≥6 months in which 118 patients (1L n = 88 and 2L+ n = 30) completed the study. Respondents completed demographic and clinical information and the following HRQoL surveys: (Short Form-12v2® Health Survey [SF-12v2], Functional Assessment of Cancer Therapy-General [FACT-G], FACT-Leukemia [FACT-Leu] Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue, and Cancer Therapy Satisfaction Questionnaire [CTSQ]). Higher scores indicate better HRQoL/treatment satisfaction. Differences in effect sizes between the two samples at the group level were calculated using Hedges' g. Medium to large positive effects were seen in the CLL Ibrutinib group on several measures compared to the Reference Study groups. The FACT-G total score was 89.2±11.1 for CLL Ibrutinib Study patients compared to 75.8±22.6 CLL Norming Tx naïve patients, 61.3±21.8 in 1L, and 61.7±20.7 in 2L+. Similar trends were seen with FACT-Leu total score and FACIT-Fatigue. CLL Ibrutinib Study patients scored higher on all CTSQ domain scores compared to the CLL Norming patients treated with other CLL therapies. We found that Ibrutinib-treatment had better HRQoL and treatment satisfaction compared to patients receiving other therapies, irrespective of line of therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
drirshad完成签到,获得积分10
1秒前
天之道完成签到,获得积分20
1秒前
AAA发布了新的文献求助30
3秒前
7秒前
7秒前
宣灵薇完成签到 ,获得积分0
10秒前
xinyuanjia的应助被Clearday采纳,获得10
10秒前
11秒前
斯文墨镜完成签到,获得积分10
11秒前
14秒前
神勇的筝发布了新的文献求助10
18秒前
韭菜馅完成签到 ,获得积分10
19秒前
一只不受管束的小狸Miao完成签到 ,获得积分10
22秒前
动听的诗翠完成签到,获得积分10
22秒前
369ninja发布了新的文献求助10
22秒前
Lsw完成签到 ,获得积分10
23秒前
Laluna的应助被suicone采纳,获得10
24秒前
爱因斯坦坦爷完成签到,获得积分10
25秒前
30秒前
和谐早晨完成签到,获得积分10
33秒前
34秒前
徐土土完成签到 ,获得积分10
35秒前
37秒前
39秒前
大鸣王潮发布了新的文献求助10
40秒前
霹雳蜗牛发布了新的文献求助10
41秒前
latata完成签到 ,获得积分10
41秒前
43秒前
俊逸的幻桃完成签到,获得积分10
45秒前
隔岸完成签到 ,获得积分10
45秒前
46秒前
铭铭完成签到,获得积分10
46秒前
li完成签到 ,获得积分10
46秒前
fangjunya完成签到 ,获得积分10
48秒前
霹雳蜗牛完成签到,获得积分10
49秒前
123发布了新的文献求助10
49秒前
369ninja发布了新的文献求助10
51秒前
Laluna的应助被suicone采纳,获得10
51秒前
大鸣王潮完成签到,获得积分10
52秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179656
求助须知:如何正确求助?哪些是违规求助? 9569921
关于积分的说明 21807706
捐赠科研通 7775141
什么是DOI,文献DOI怎么找? 3433072
关于科研通互助平台的介绍 2557032
邀请新用户注册赠送积分活动 2478778